Interestingly, untargeted alpha therapy with 225Ac-DOTA-Trastuzumab had a slight effect on tumor growth inhibition compared to targeted 225Ac-DOTA-CD38, but a lower median survival (75 days) compared to CS1 CAR T plus TAT (89 days). Here, CD38 is linked to neoplasm.